Search results
Results From The WOW.Com Content Network
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating ...
Inovio's net loss for the third quarter of 2024 was $25.2 million, or $0.89 per share, basic and dilutive, compared to a net loss of $33.9 million, or $1.52 per share, basic and dilutive, for the ...
Inovio Pharmaceuticals Inc (NASDAQ:INO) reported its latest quarterly earnings results after the bell Wednesday, with revenue and earnings rising year-over-year. The pharmaceutical company ...
On 26 August 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil. [10] On 26 October 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history.
The stock of Inovio Pharmaceuticals (NAS:INO, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation.
As of 2020, Inovio Pharmaceuticals is developing a synthetic multi-antigen DNA vaccine covering HCV genotypes 1a and 1b and targeting the HCV antigens nonstructural protein 3 and 4A (), as well as NS4B and NS5A proteins.
Inovio Pharmaceuticals and Roche announced last month that they have reached an agreement to develop and commercialize multi-antigen DNA immunotherapies. Invovio is a development stage ...
For premium support please call: 800-290-4726 more ways to reach us